ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "3aba6ee7-9298-4b3c-817b-88692ff33cc1"}, "_deposit": {"id": "2002130", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2002130"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:02002130", "sets": ["1646019880489"]}, "author_link": [], "control_number": "2002130", "item_1615768549627": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "179", "bibliographicPageStart": "169", "bibliographicVolumeNumber": "84", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science", "bibliographic_titleLang": "en"}]}]}, "item_9_description_4": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "Ulcerative colitis (UC) is an incurable, chronic inflammatory disease of the large bowel whose etiology and pathogenesis have not yet been comprehensively explained. Tofacitinib is a small molecule Janus kinase inhibitor that was introduced for treating refractory UC. We aimed to examine the efficacy and safety of tofacitinib for the treatment of 18 patients with UC. Continuous treatment rates were 50, 38, and 33% at 8, 24, and 52 weeks, respectively. Overall, 83.3% of these patients showed tumor necrosis factor (TNF) antibody failure status. When the effective status was defined as a Lichtiger index (LI) that decreased by 3 points or more or was less than 4 points and remission status was defined as an LI less than 4 points, the effective and remission rates (%) at 2, 8, and 16 weeks were 55.5 (10/18) and 22.2 (4/18), 38.8 (7/18) and 33.3 (6/18), and 38.8 (7/18) and 38.8 (7/18), respectively. Background characteristics of 2-week responders and non-responders were compared. C-reactive protein level in responders was significantly lower than that in non-responders, and the hemoglobin level in responders was significantly higher than that in non-responders. This study provides preliminary results of the effectiveness of tofacitinib even for TNF antibody and tacrolimus failure patients.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}, {"subitem_description": "This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/).", "subitem_description_language": "en", "subitem_description_type": "Other"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.84.1.169", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine", "subitem_publisher_language": "en"}]}, "item_9_relation_43": {"attribute_name": "関連情報", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/841.html", "subitem_relation_type_select": "URI"}}]}, "item_9_source_id_7": {"attribute_name": "収録物識別子", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "PISSN"}, {"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "EISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakamura, Masanao", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Yamamura, Takeshi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Maeda, Keiko", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Sawada, Tsunaki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Mizutani, Yasuyuki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ishikawa, Eri", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ishikawa, Takuya", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kakushima, Naomi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Furukawa, Kazuhiro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ohno, Eizaburo", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kawashima, Hiroki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Honda, Takashi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ishigami, Masatoshi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Fujishiro, Mitsuhiro", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "date": [{"dateType": "Available", "dateValue": "2022-02-28"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "18_Nakamura.pdf", "filesize": [{"value": "4.2 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "application/pdf", "size": 4200000.0, "url": {"objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/2002130/files/18_Nakamura.pdf"}, "version_id": "03f1161d-6f8c-468d-adb4-d45a437b17f6"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "ulcerative colitis", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "refractory", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tofacitinib", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "case reports", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis", "subitem_title_language": "en"}]}, "item_type_id": "40001", "owner": "1", "path": ["1646019880489"], "permalink_uri": "https://doi.org/10.18999/nagjms.84.1.169", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2022-02-28"}, "publish_date": "2022-02-28", "publish_status": "0", "recid": "2002130", "relation": {}, "relation_version_is_last": true, "title": ["Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 84(1)

Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis

https://doi.org/10.18999/nagjms.84.1.169
https://doi.org/10.18999/nagjms.84.1.169
e3d2dc4e-e390-4517-b877-eedeb7e5bff0
名前 / ファイル ライセンス アクション
18_Nakamura.pdf 18_Nakamura.pdf (4.2 MB)
Item type itemtype_ver1(1)
公開日 2022-02-28
タイトル
タイトル Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
言語 en
著者 Nakamura, Masanao

× Nakamura, Masanao

en Nakamura, Masanao

Search repository
Yamamura, Takeshi

× Yamamura, Takeshi

en Yamamura, Takeshi

Search repository
Maeda, Keiko

× Maeda, Keiko

en Maeda, Keiko

Search repository
Sawada, Tsunaki

× Sawada, Tsunaki

en Sawada, Tsunaki

Search repository
Mizutani, Yasuyuki

× Mizutani, Yasuyuki

en Mizutani, Yasuyuki

Search repository
Ishikawa, Eri

× Ishikawa, Eri

en Ishikawa, Eri

Search repository
Ishikawa, Takuya

× Ishikawa, Takuya

en Ishikawa, Takuya

Search repository
Kakushima, Naomi

× Kakushima, Naomi

en Kakushima, Naomi

Search repository
Furukawa, Kazuhiro

× Furukawa, Kazuhiro

en Furukawa, Kazuhiro

Search repository
Ohno, Eizaburo

× Ohno, Eizaburo

en Ohno, Eizaburo

Search repository
Kawashima, Hiroki

× Kawashima, Hiroki

en Kawashima, Hiroki

Search repository
Honda, Takashi

× Honda, Takashi

en Honda, Takashi

Search repository
Ishigami, Masatoshi

× Ishigami, Masatoshi

en Ishigami, Masatoshi

Search repository
Fujishiro, Mitsuhiro

× Fujishiro, Mitsuhiro

en Fujishiro, Mitsuhiro

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
キーワード
言語 en
主題Scheme Other
主題 ulcerative colitis
キーワード
言語 en
主題Scheme Other
主題 refractory
キーワード
言語 en
主題Scheme Other
主題 tofacitinib
キーワード
言語 en
主題Scheme Other
主題 case reports
内容記述
内容記述 Ulcerative colitis (UC) is an incurable, chronic inflammatory disease of the large bowel whose etiology and pathogenesis have not yet been comprehensively explained. Tofacitinib is a small molecule Janus kinase inhibitor that was introduced for treating refractory UC. We aimed to examine the efficacy and safety of tofacitinib for the treatment of 18 patients with UC. Continuous treatment rates were 50, 38, and 33% at 8, 24, and 52 weeks, respectively. Overall, 83.3% of these patients showed tumor necrosis factor (TNF) antibody failure status. When the effective status was defined as a Lichtiger index (LI) that decreased by 3 points or more or was less than 4 points and remission status was defined as an LI less than 4 points, the effective and remission rates (%) at 2, 8, and 16 weeks were 55.5 (10/18) and 22.2 (4/18), 38.8 (7/18) and 33.3 (6/18), and 38.8 (7/18) and 38.8 (7/18), respectively. Background characteristics of 2-week responders and non-responders were compared. C-reactive protein level in responders was significantly lower than that in non-responders, and the hemoglobin level in responders was significantly higher than that in non-responders. This study provides preliminary results of the effectiveness of tofacitinib even for TNF antibody and tacrolimus failure patients.
言語 en
内容記述タイプ Abstract
内容記述
内容記述 This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/).
言語 en
内容記述タイプ Other
出版者
言語 en
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
ID登録
ID登録 10.18999/nagjms.84.1.169
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/841.html
収録物識別子
収録物識別子タイプ PISSN
収録物識別子 0027-7622
収録物識別子
収録物識別子タイプ EISSN
収録物識別子 2186-3326
書誌情報 en : Nagoya Journal of Medical Science

巻 84, 号 1, p. 169-179, 発行日 2022-02
戻る
0
views
See details
Views

Versions

Ver.1 2022-02-28 04:30:31.226616
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3